You are seeing these quotes based on previous browsing related to sectors such as
| Latest | Forecast | |
|---|---|---|
| Div Yield | 0.0% | n/a |
| Div Cover | n/a | n/a |
| Op Mrgn | 2.2% | n/a |
| ROCE | 2.8% |
| Latest | Forecast | |
|---|---|---|
| P/E | 29.9 | n/a |
| PEG | 0.0 | n/a |
| Price / Revenue | 3.7 | n/a |
| Price / Book value | 4.2 |
| Latest | Forecast | |
|---|---|---|
| Revenue | 96.5% | 11.5% |
| PBT | 0.0% | n/a |
| EPS | 0.0% | 44.1% |
| DPS | n/a | 0.0% |
| Year Ending | Revenue ($m) |
Pre-tax ($m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 2019-12-31 | 204.89 | -141.10 | $-0.16 | -31.5 | 0.0 | n/a | n/a | 0.0% |
| 2020-12-31 | 227.98 | -189.73 | $-0.18 | -34.9 | 0.0 | n/a | n/a | 0.0% |
| 2021-12-31 | 356.13 | -215.74 | $0.00 | -2,840.3 | 0.0 | n/a | n/a | 0.0% |
| 2022-12-31 | 426.41 | -410.42 | $-0.43 | -7.4 | 0.0 | n/a | n/a | 0.0% |
| 2023-12-31 | 838.00 | 58.31 | $0.12 | 30.0 | 0.0 | n/a | n/a | 0.0% |
| Hutchmed to receive $20m Fruzaqla milestone payment Sharecast News | 31 Oct |
|---|---|
| Hutchmed reports positive results from AstraZeneca lung cancer collaboration Sharecast News | 16 Oct |
| Hutchmed partner Takeda gets Japanese approval for Fruzaqla Sharecast News | 24 Sep |
| Appointment of Independent Non-executive Director | 20-Nov-24 09:30 |
|---|---|
| Total Voting Rights | 31-Oct-24 08:30 |
| Vesting of awards under the LTIP | 21-Oct-24 09:30 |
| SAVANNAH: clinically meaningful response rate | 16-Oct-24 07:01 |
| Japan Approval for FRUZAQLA | 24-Sep-24 08:00 |